• Adult Leukemia Program

    Dana-Farber/Brigham and Women's Cancer Care

    The Adult Leukemia program is part of the Hematologic Oncology (Blood Cancers) Treatment Center. Our specialists are highly experienced in treating patients with acute and chronic leukemia, myeloproliferative disorders and myelodysplastic syndromes.

    About the Program

    The Adult Leukemia Program provides care for patients with leukemia, such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and related bone marrow disorders, including myelodysplasia and myelofibrosis. Our program is one of the most experienced in the nation, with a high volume of consultations, patients cared for, and clinical trials offered. Through our program of clinical research, we apply our ongoing understanding of leukemia to developing therapies that will benefit patients today and in the future.

    Our Treatment Approach

    The Adult Leukemia Program provides comprehensive services for patients with acute leukemia and related disorders. These include:

    • evaluation and diagnosis of individuals with any type of bone-marrow disorder, including acute and chronic leukemias, myeloproliferative disorders, and myelodysplastic syndromes
    • evaluation and diagnosis of patients with unexplained anemia, or abnormal white blood or platelet counts
    • development and implementation of a personalized treatment plan, ranging from standard supportive care to intensive chemotherapy for acute leukemia
    • access to new therapies through clinical trials 
    • comprehensive bone marrow/stem cell transplantation services
    • support services
    • access to complementary therapies through the Leonard P. Zakim Center for Integrated Therapies 
    • follow-up care, including collaboration with your local (referring) physician
     

    The Treatment Team

    A highly focused and experienced team of physicians, practitioners and clinical researchers work to provide state-of-the-art compassionate care with an emphasis on cutting-edge clinical research. Physicians work closely with research scientists in a "bench-to-bedside" approach that identifies promising new treatments by rapidly translating laboratory discoveries into the clinical setting.

    Adult Leukemia Program Leadership

    Richard M. Stone, MD, Program Director
    Daniel J. DeAngelo, MD, PhD, Director, Clinical and Translational Research
    Martha Wadleigh, MD, Clinical Director

    Adult Leukemia Physicians

    Gregory Abel, MD
    David P. Steensma, MD
    Richard M. Stone, MD
    Martha Wadleigh, MD 

    Research Scientists

    Benjamin Ebert, MD, PhD
    David A. Frank, MD, PhD
    Andrew Lane, MD, PhD
    R. Coleman Lindsley, MD, PhD
    James Griffin, MD, Chair, Department of Medical Oncology
    Anthony G. Letai, MD, PhD 
    Ann Mullally, MD
    David Weinstock, MD 

    Adult Leukemia Nursing and Physician Assistant Team

    Susan Buchanan, PA-C, MHP
    Sarah Cahill, PA-C
    Katherine Edmonds, ARNP
    Ilene Galinsky, MSN, ANP-C
    Adriana Penicaud, PA-C

    We work closely with our transplant service team when patients require bone marrow/stem cell transplantation.

     

    Clinical Research

    The clinical research mission of the Adult Leukemia Program is to develop and bring new and better therapies to patients. At any given time, the program offers patients a wide array of opportunities to participate in clinical research studies relating to all stages and types of leukemia and related disorders. Patients have access to trials that originate within Dana-Farber/Brigham and Women's Cancer Center and other Harvard-affiliated institutions, those sponsored by private industry, as well as those that are part of a collaborative effort, such as the Cancer and Leukemia Group B, of which the program is a member.

    Physician-researchers within the program are currently involved in a number of exciting avenues of investigation, which include targeted therapies aimed at making cancer treatment more specific and less toxic. These include:

    • immunotherapy for acute leukemia and myelodysplasia involving agents such as interleukin-2 and autologous vaccines
    • integrating antibody-based therapy against leukemia cells with standard chemotherapy
    • promoting the differentiation or normal growth of bone marrow cells in patients with myelodysplasia
    • working with molecules that interrupt the normal cascade of biochemical signals within the cell that promote the growth of leukemia

    Other innovative offerings include treating adults with acute lymphoblastic leukemia by applying the principles used in successful pediatric treatments of this condition and clinical trials and treatments specialized for older adults.

    See current clinical trials for leukemia and myelodysplastic syndromes at Dana-Farber 

     

    Contact Us

    New Patients

    Leukemia: 617-632-6028 or 617-632-5138, or use this online form to make an appointment.

    Current Patients

    Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.

    Fax

    617-632-3730 

    Mailing address

    Hematologic Malignancies Division
    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

     
     
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • New adult leukemia patients:
      617-632-6028 or 617-632-5138 
    • Or complete the online form.
     
  • Highest ranked in New England

  • Rapid Heme Panel: A Major Advance in Blood Cancer Testing

    • leukemia cellsPhysicians at Dana-Farber/
      Brigham and Women's Cancer Center (DF/BWCC) have begun using Rapid Heme Panel, a high-tech genetic test that provides, within a matter of days, critical information to aid the choice of treatment.